Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024

NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, announced today that it will host a webinar, Understanding the Genetic Validation for IL-6 Inhibition in Cardiovascular Disease, featuring Dr. Dipender Gill, CEO and Founder of Sequoia Genetics. The webinar will be held on Friday, November ...